Author

K. M. Moore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

M. Lee· 2 shared M. S. Suthar· 2 shared A. Grakoui· 1 shared A. Metz· 1 shared A. Naji· 1 shared A. Piantadosi· 1 shared A. R. Henry· 1 shared A.-N. Pelletier· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

M. Lee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single cell analysis reveals an antiviral network that controls Zika virus infection in human dendritic cells

K. M. Moore, A.-N. Pelletier, S. Lapp, A. Metz, G. K. Tharp, M. Lee, S. S. Bhasin, M. Bhasin, R.-P. Sekaly, S. E. Bosinger, M. S. Suthar

The paper uses scRNA-seq to analyze the antiviral response in human dendritic cells infected with ZIKV, identifying a network of host genes and proteins involved in antiviral defense.

bioRxiv · Jan 19, 2024Microbiology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

V.-V. Edara, K. E. Manning, M. Ellis, L. Lai, K. M. Moore, S. L. Foster, K. Floyd, M. E. Davis-Gardner, G. Mantus, L. E. Nyhoff, S. Bechnack, G. Alaaeddine, A. Naji, H. Samaha, M. Lee, , M. S. Suthar

This study evaluates the neutralizing activity of mRNA vaccines against the SARS-CoV-2 Omicron variant, showing reduced efficacy after the second dose but improved responses following a third dose.

bioRxiv · Dec 20, 2021Immunology